Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30018042 | 1.00 | HSD11B1 (0.33) | HSD11B1 | |
| SCHEMBL29175308 | 0.78 | — | — | |
| SCHEMBL31281224 | 0.74 | HSD11B1 (0.31) | HSD11B1 | |
| SCHEMBL231670 | 0.73 | — | — | |
| SCHEMBL8337731 | 0.71 | — | — | |
| SCHEMBL2466483 | 0.71 | — | — | |
| SCHEMBL29264263 | 0.70 | — | — | |
| SCHEMBL4885993 | 0.69 | — | — | |
| SCHEMBL29518186 | 0.68 | HSD11B1 (0.33) | HSD11B1 | |
| SCHEMBL4369108 | 0.67 | HSD11B1 (0.33) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4229639-A1 | METHOD AND SYSTEMS FOR PHYTOMEDICINE ANALYTICS FOR RESEARCH OPTIMIZATION AT SCALE | GBS Global Biopharma, Inc. (CA) | 2023-08-23 | — | — | EP | claimed |
| WO-2022081889-A1 | METHOD AND SYSTEMS FOR PHYTOMEDICINE ANALYTICS FOR RESEARCH OPTIMIZATION AT SCALE | GBS GLOBAL BIOPHARMA, INC. (CA) | 2022-04-21 | — | — | WO | claimed |
| WO-2022081889-A1 | METHOD AND SYSTEMS FOR PHYTOMEDICINE ANALYTICS FOR RESEARCH OPTIMIZATION AT SCALE | GBS GLOBAL BIOPHARMA, INC. (CA) | 2022-04-21 | — | — | WO | disclosed |
| EP-1390332-B1 | UNCATALYSED ADDITION REACTIONS | JOHNSON MATTHEY PLC (GB) | 2009-01-07 | — | — | EP | disclosed |
| CN-1257143-C | Uncatalysed addition reactions | JOHNSON MATTHEY PLC (GB) | 2006-05-24 | — | — | CN | disclosed |
| US-6867335-B2 | Uncatalysed addition reactions | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2005-03-15 | — | — | US | disclosed |
| US-20040210076-A1 | Uncatalysed addition reactions | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2004-10-21 | — | — | US | disclosed |
| CN-1511130-A | Addition reaction without catalyst | Լ��ѷ | 2004-07-07 | — | — | CN | disclosed |
| EP-0365988-B1 | Developing solvent for layers which are crosslinkable by photopolymerization, and process for the production of relief printing forms | DU PONT (US) | 1994-06-15 | — | — | EP | disclosed |
| EP-0365988-A2 | Developing solvent for layers which are crosslinkable by photopolymerization, and process for the production of relief printing forms | E.I. DU PONT DE NEMOURS & COMPANY INCORPORATED (US) | 1990-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040210076-A1 | Uncatalysed addition reactions | SQLE, XDH, DCXR | HSD11B1 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.